Portland, OR (PRWEB) April 19, 2017
Nobilis Therapeutics Announces Completion of Landmark NBTX-001 Clinical Trial in 81 Patients with Panic Disorder
Company Seeks to Leverage Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial
Nobilis Therapeutics, Inc. announced today the completion and formal registration of an 81 patient clinical trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of Panic Disorder.
Panic disorder is an anxiety disorder where sufferers experience sudden or extreme fear – a severe panic attack -- with no prior warning. Lifetime prevalence estimates for panic disorder in US adults range from 2.0% to 6.0%.
This disorder is treated with drugs such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs) (drugs of first choice) and benzodiazepine tranquilizers (drugs of second choice), but these drugs treat only the symptoms of the disease, have numerous adverse side effects, and in many cases are wholly ineffective.
In contrast to conventional treatments, NBTX-001 is based on xenon, a noble gas that has no known toxicity or adverse reactions at the concentrations used in the study.
“Completion and registration of this landmark study is a significant milestone for Nobilis Therapeutics, which, to our knowledge, is the only company pursuing noble gas-based interventions to treat psychiatric and neurodegenerative disorders,” said Vlad Bogin, MD, FACP, CEO of Nobilis Therapeutics. “We look forward to leveraging the important information gained from this trial to pursue additional indications, such as Post Traumatic Stress Disorder (PTSD).”
In March, 2016, Nobilis Therapeutics entered into an exclusive licensing agreement with Harvard University to utilize its intellectual property for treatment of PTSD. Preclinical animal data covered in the licensed patent was published in a peer reviewed journal. The Company is currently planning to conduct clinical trials in patients with PTSD, a disease with similar molecular pathologies to panic disorder.
“NBTX-001 selectively blocks biological pathways in the brain that are associated with stress, fear, and inflammation. Xenon, its active ingredient, has been widely used for medical imaging at similar concentrations. Given its excellent safety profile, favorable pharmacokinetics, and lack of off-target effects, we believe that NBTX-001 will become an excellent alternative to existing psychiatric drugs,” said Thomas Ichim, Ph.D, Chief Scientific Officer of Nobilis Therapeutics.
The clinical trial was registered in the WHO recognized ISRCTN clinical trials registry.
About Nobilis Therapeutics, Inc.
Nobilis Therapeutics is a biotechnology company that is focused on development and commercialization of proprietary inhalation-based treatments using controlled device administration of inert gases that have an exceptional safety profile proven by decades of clinical use. The Company has filed multiple patents on the use of inert gases for treatment of a variety of psychiatric and neurodegenerative diseases and leverages the experience of its international team that has successfully used this technology in the treatment of over 500 patients for conditions ranging from panic attacks to substance abuse.
Vlad Bogin, MD, FACP
3042NW Monte Vista Terrace
Portland, OR 97210
Tel: (971) 229-1679
Read the full story at http://www.prweb.com/releases/2017/04/prweb14254174.htm.
Copyright©2017 Vocus, Inc.
All rights reserved